CTLT / Catalent (CTLT) Gains Post Deal With Elliott and Earnings Report

Catalent, Inc.'s revenue and scale have suffered due to the decline in vaccine deliveries, particularly in its Biologics segment. The company reported more_horizontal

Catalent's (CTLT) product and service launches and a slew of strategic deals raise optimism about the stock. more_horizontal

Elliott recently entered a cooperation agreement with Catalent. This could pave the way for some major changes at the pharmaceutical company. more_horizontal

Drug manufacturer Catalent Inc. CTLT, +1.74% said Friday it has received a notice from the New York Stock Exchange informing it that's it's not in com more_horizontal

The company delivered a better-than-expected quarterly earnings report. It beat on revenue, and only narrowly missed on earnings. more_horizontal

Catalent's (CTLT) deal with Elliott and earnings report boost its shares. The company will likely improve its value and growth with the agreement and more_horizontal

The contract drug manufacturer posted steep declines in key fundamentals in its fiscal fourth quarter. Still, it booked more revenue than analysts exp more_horizontal

Catalent, Inc. (NYSE:CTLT ) Q4 2023 Earnings Conference Call August 29, 2023 8:15 AM ET Company Participants Paul Surdez - Vice President, Investor Re more_horizontal